Characteristics of the activator sites of liver and muscle phosphorylase b were probed by using AMP and AMP analogs in kinetic studies, by quantitative affinity chromatography, and by reaction with an affinity-labeling reagent. Activation of liver phosphorylase b by N6-(6-aminohexyl)AMP in comparison with AMP and other analogs is explained by preferential binding to the activator site. The KM value for glucose-1-P of liver phosphorylase b activated with N6-(6-aminohexyl)AMP is considerably higher than that of muscle phosphorylase b. Affinity chromatography utilizing AMP-Sepharose suggests that the activator site is less well formed in liver phosphorylase than in muscle phosphorylase. Reaction with 8-[m-(m-fluorosulfonylbenzamido)benzylthio]adenine activates liver phosphorylase b and is consistent with the reaction at the activator site. The results suggest that part of the reason that liver phosphorylase b is not activated by AMP and AMP analogs is due to a poor coupling between the activator and active sites. Lack of good activation by AMP also can be explained by binding at the inhibitor site.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (1982) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: